A longitudinal and cross‐sectional study of plasma neurofilament light chain concentration in Charcot‐Marie‐Tooth disease

Advances in genetic technology and small molecule drug development have paved the way for clinical trials in Charcot‐Marie‐Tooth disease (CMT); however, the current FDA‐approved clinical trial outcome measures are insensitive to detect a meaningful clinical response. There is, therefore, a need to identify sensitive outcome measures or clinically relevant biomarkers. The aim of this study was to further evaluate plasma neurofilament light chain (NFL) as a disease biomarker in CMT. Plasma NFL was measured using SIMOA technology in both a cross‐sectional study of a US cohort of CMT patients and longitudinally over 6 years in a UK CMT cohort. In addition, plasma NFL was measured longitudinally in two mouse models of CMT2D. Plasma concentrations of NFL were increased in a US cohort of patients with CMT1B, CMT1X and CMT2A but not CMT2E compared with controls. In a separate UK cohort, over a 6‐year interval, there was no significant change in plasma NFL concentration in CMT1A or HSN1, but a small but significant reduction in patients with CMT1X. Plasma NFL was increased in wild type compared to GARSC201R mice. There was no significant difference in plasma NFL in GARSP278KY compared to wild type mice. In patients with CMT1A, the small difference in cross‐sectional NFL concentration vs healthy controls and the lack of change over time suggests that plasma NFL may lack sufficient sensitivity to detect a clinically meaningful treatment response in adulthood.

[1]  M. Stavrou,et al.  Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies , 2021, International journal of molecular sciences.

[2]  H. Zetterberg,et al.  AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy , 2021, Gene Therapy.

[3]  K. Blennow,et al.  Plasma neurofilament light chain as a potential biomarker in Charcot‐Marie‐Tooth disease , 2020, European journal of neurology.

[4]  David John Adams,et al.  Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis , 2020, Neurology.

[5]  G. Schiavo,et al.  Developmental demands contribute to early neuromuscular degeneration in CMT2D mice , 2020, Cell Death & Disease.

[6]  K. Blennow,et al.  Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease , 2020, Alzheimer's & Dementia.

[7]  M. Shy,et al.  Are we prepared for clinical trials in Charcot-Marie-Tooth disease? , 2019, Brain Research.

[8]  J. Svaren,et al.  Transmembrane protease serine 5: a novel Schwann cell plasma marker for CMT1A , 2019, Annals of clinical and translational neurology.

[9]  K. Refshauge,et al.  Development and validation of the Charcot-Marie-Tooth Disease Infant Scale , 2018, Brain : a journal of neurology.

[10]  D. Herrmann,et al.  The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM) , 2018, Neurology.

[11]  P. Nopoulos,et al.  Validation of MRC Centre MRI calf muscle fat fraction protocol as an outcome measure in CMT1A , 2018, Neurology.

[12]  M. Mcdermott,et al.  The Charcot–Marie–Tooth Health Index: Evaluation of a Patient‐Reported Outcome , 2018, Annals of neurology.

[13]  R. Magliozzi,et al.  Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies , 2018, Journal of the peripheral nervous system : JPNS.

[14]  K. Blennow,et al.  Plasma neurofilament light chain concentration in the inherited peripheral neuropathies , 2018, Neurology.

[15]  Ludwig Kappos,et al.  Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis , 2017, Annals of neurology.

[16]  K. Blennow,et al.  Blood-based NfL , 2017, Neurology.

[17]  M. Jorge Cardoso,et al.  Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia , 2016, Neurology.

[18]  D. Radice,et al.  Responsiveness of clinical outcome measures in Charcot−Marie−Tooth disease , 2015, European journal of neurology.

[19]  P. Wong,et al.  Susceptibility-weighted MRI in mild traumatic brain injury , 2015, Neurology.

[20]  Michael A. Gonzalez,et al.  Reduced neurofilament expression in cutaneous nerve fibers of patients with CMT2E , 2015, Neurology.

[21]  J. Gore,et al.  Proximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseases , 2014, Neurology.

[22]  R. Finkel,et al.  Validation of the Charcot–Marie–Tooth disease pediatric scale as an outcome measure of disability , 2012, Annals of neurology.

[23]  P. Chinnery,et al.  Charcot–Marie–Tooth disease in Northern England , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  M. Mcdermott,et al.  Reliability of the CMT neuropathy score (second version) in Charcot‐Marie‐Tooth disease , 2011, Journal of the peripheral nervous system : JPNS.

[25]  M. Z. Cader,et al.  An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy , 2009, Disease Models & Mechanisms.

[26]  K. Terasawa,et al.  Human erythrocytes possess a cytoplasmic endoskeleton containing beta-actin and neurofilament protein. , 2006, Archives of histology and cytology.

[27]  R. Burgess,et al.  An Active Dominant Mutation of Glycyl-tRNA Synthetase Causes Neuropathy in a Charcot-Marie-Tooth 2D Mouse Model , 2006, Neuron.

[28]  A. Petzold.  Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss , 2005, Journal of the Neurological Sciences.

[29]  C. Angiari,et al.  Giant axon and neurofilament accumulation in Charcot–Marie–Tooth disease type 2E , 2004, Neurology.

[30]  T. Yousry,et al.  MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. , 2016, The Lancet. Neurology.